MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • The Remarkable Pro-Drug From VistaGen Therapeutics (VSTA) 0 comments
    Mar 15, 2012 3:04 PM | about stocks: VTGN

    Currently in Phase 1b clinical development, VistaGen Therapeutics' lead drug candidate, AV-101, is showing promising potential for the treatment of neuropathic pain and depression. These are huge markets with notable growth prospects, and the unique properties of AV-101 continue to be tested and verified.

    One of the most notable properties of AV-101 is its ability to essentially trick the body into letting it get past the formidable blood-brain barrier, a separation of the body's blood circulation from the brain extracellular fluid in the central nervous system. The blood-brain barrier has long represented a major obstacle for drug manufacturers seeking ways to treat nerve and brain related diseases. Because of its extraordinary chemical design, AV-101 is able to readily cross this barrier. It is then converted into a variation of itself, a chemical which does the work needed to be done, such as relieving neuropathic pain. AV-101's development plan is such that it can allow Phase 1 safety studies to support potential Phase 2 development for the treatment of other neurological conditions, such as epilepsy, Parkinson's disease, Huntington's disease, and depression.

    AV-101 highlights include the following:

    • Readily crosses the blood-brain barrier

    • Anticonvulsant that protects against NMDA receptor-mediated neurotoxicity

    • Preferentially converted to the GlyB antagonist, 7-Cl-KYNA, by activated glial cells at the desired sites of therapeutic action, thereby reducing the potential risk of side effects even in chronic treatment regimens

    • A pro-drug with no therapeutic activity until metabolic conversion

    • Generates therapeutically-meaningful brain levels of 7-Cl-KYNA with oral administration

    • Converted to 4-Cl-3-hydroxyanthranilic acid, which blocks the synthesis of quinolinic acid (an endogenous convulsant and NMDA receptor agonist) which may further reduce glutamatergic toxicity associated with epilepsy and other neurodegenerative diseases

    • Antagonists of the GlyB site, such as 7-Cl-KYNA, have a favorable safety profile compared to other NMDA receptor antagonists

    • May stimulate the expression and/or development of dopamine positive neurons

    • Comparable efficacy to gabapentin in three animal models of neuropathic pain

    For additional information, visit the company's website at www.VistaGen.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: VTGN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.